Cited by 678Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

Shigematsu, Hisayuki, Takahashi, Takao, Nomura, Masaharu, Majmudar, Kuntal, Suzuki, Makoto, Lee, Huei, Wistuba, Ignacio I., Fong, Kwun M., Toyooka, Shinichi, Shimizu, Nobuyoshi, Fujisawa, Takehiko, Minna, John D., Gazdar, Adi F.·2005·Cancer Research

DOI 10.1158/0008-5472.can-04-4235

Open this paper in CoChat — free account

Abstract

Mutations in the epidermal growth factor receptor gene (EGFR) in lung cancers predict for sensitivity to EGFR kinase inhibitors. HER2 (also known as NEU, EGFR2, or ERBB2) is a member of the EGFR family of receptor tyrosine kinases and plays important roles in the pathogenesis of certain human cancers, and mutations have recently been reported in lung cancers. We sequenced the tyrosine kinase domain of HER2 in 671 primary non-small cell lung cancers (NSCLC), 80 NSCLC cell lines, and 55 SCLCs and other neuroendocrine lung tumors as well as 85 other epithelial cancers (breast, bladder, prostate, and colorectal cancers) and compared the mutational status with clinicopathologic features and the presence of EGFR or KRAS mutations. HER2 mutations were present in 1.6% (11 of 671) of NSCLC and were absent in other types of cancers. Only one adenocarcinoma cell line (NCI-H1781) had a mutation. All HER2 mutations were in-frame insertions in exon 20 and target the identical corresponding region as did EGFR insertions. HER2 mutations were significantly more frequent in never smokers (3.2%, 8 of 248; P=0.02) and adenocarcinoma histology (2.8%, 11 of 394; P=0.003). In 394 adenocarcinoma cases, HER2 mutations preferentially targeted Oriental ethnicity (3.9%) compared with other ethnicities (0.7%), female gender (3.6%) compared with male gender (1.9%) and never smokers (4.1%) compared with smokers (1.4%). Mutations in EGFR, HER2, and KRAS genes were never present together in individual tumors and cell lines. The remarkable similarities of mutations in EGFR and HER2 genes involving tumor type and subtype, mutation type, gene location, and specific patient subpopulations targeted are unprecedented and suggest similar etiologic factors. EGFR, HER2, and KRAS mutations are mutually exclusive, suggesting different pathways to lung cancer in smokers and never smokers.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-04-4235

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · CHEST Journal · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citation

Show all 28 references

Sorted by citations

Items 301–400 of 678

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
Park, Y. H., Shin, H., Jung, H. H., Choi, Y., Ahn, T., Park, K., Lee, A., Do, I., Kim, J., Ahn, J. S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5184 · Cited by 36
Clinical and genetic features of lung squamous cell cancer in never-smokers
Huang, Y., Wang, R., Pan, Y., Zhang, Y., Li, H., Cheng, C., Zheng, D., Zheng, S., Li, Y., Shen, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8745 · Cited by 34
Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland
Große, A., Große, C., Rechsteiner, M., & Soltermann, A. (2019) · Diagnostic Pathology · doi:10.1186/s13000-019-0789-1 · Cited by 35
Molecular features of lung adenocarcinoma in young patients
Chen, Z., Teng, X., Zhang, J., Huang, K., Shen, Q., Luo, H., Luo, H., Yuan, Y., & Teng, X. (2019) · BMC Cancer · doi:10.1186/s12885-019-5978-5 · Cited by 34
Targeting HER2 genomic alterations in non-small cell lung cancer
Zeng, J., Ma, W., Young, R. B., & Li, T. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.04.001 · Cited by 37
Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients
Liu, Z., Wu, L., Cao, J., Yang, Z., Zhou, C., Cao, L., Wu, H., Shen, H., Jin, M., Zhang, Y., et al. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s173391 · Cited by 33
Impact of HER2 and EGFR gene status on gefitinib‐treated patients with nonsmall‐cell lung cancer
Soh, J., Toyooka, S., Ichihara, S., Fujiwara, Y., Hotta, K., Suehisa, H., Kobayashi, N., Ichimura, K., Aoe, K., Aoe, M., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22818 · Cited by 33
Self-citation
Targetable “Driver” Mutations in Non Small Cell Lung Cancer
Vijayalakshmi, R., & Krishnamurthy, A. (2011) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-011-0108-0 · Cited by 33
Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy
Yamaguchi, F., Kugawa, S., Tateno, H., Kokubu, F., & Fukuchi, K. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.08.014 · Cited by 33
Nile Tilapia Derived TP4 Shows Broad Cytotoxicity toward to Non-Small-Cell Lung Cancer Cells
Ting, C.-H., & Chen, J. (2018) · Marine Drugs · doi:10.3390/md16120506 · Cited by 32
Recent developments related to the EGFR as a target for cancer chemotherapy
Speake, G., Holloway, B. R., & Costello, G. F. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.02.007 · Cited by 32
The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population
Jo, U., Han, S. G. L., Seo, J. H., Park, K. H., Lee, J. W., Lee, H., Ryu, J., & Kim, Y. H. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-359 · Cited by 32
Self-citation
Somatic Mutations in Human Cancer: Insights from Resequencing the Protein Kinase Gene FamilyPreprint
Futreal, P. A., Wooster, R., & Stratton, M. R. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.015 · Cited by 32
Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer
Nakata, A., & Gotoh, N. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.697155 · Cited by 31
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: an update for recent advances in therapeutics
Chung, C. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215577810 · Cited by 31
Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
Ou, S. I. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201296 · Cited by 31
Clinical outcomes of patients with HER2 -mutant advanced lung cancer: chemotherapies versus HER2 -directed therapies
Zhou, J., Ding, N., Xu, X., Zhang, Y., Ye, M., Li, C., & Hu, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936090 · Cited by 31
Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor
Jang, J., Son, J., Park, E., Kosaka, T., Saxon, J. A., Clercq, D. J. H. D., Choi, H. G., Tanizaki, J., Eck, M. J., Janne, P. A., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201805187 · Cited by 32
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer
Lee, S., Menis, J., Kim, T. M., Kim, H. R., Zhou, C., Kurniawati, S., Prabhash, K., Hayashi, H., Lee, D. D.-W., Imasa, M. S. B., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103996 · Cited by 33
Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum
Ruiz-Sáenz, A., Sandhu, M., Carrasco, Y. P., Maglathlin, R. L., Taunton, J., & Moasser, M. M. (2015) · Oncogene · doi:10.1038/onc.2014.455 · Cited by 30
Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer
Kumar, M., Ernani, V., & Owonikoko, T. K. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.06.009 · Cited by 31
Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway
Ohtsuka, T., Sakaguchi, M., Yamamoto, H., Tomida, S., Takata, K., Shien, K., Hashida, S., Miyata‐Takata, T., Watanabe, M., Suzawa, K., et al. (2016) · Scientific Reports · doi:10.1038/srep39557 · Cited by 30
Self-citation
Recent Advances in Personalized Lung Cancer Medicine
Okimoto, R. A., & Bivona, T. G. (2014) · Personalized Medicine · doi:10.2217/pme.14.19 · Cited by 29
The End of Nihilism: Systemic Therapy of Advanced Non–Small Cell Lung Cancer
Ernani, V., Steuer, C. E., & Jahanzeb, M. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-102442 · Cited by 29
Oncogenic potential of human pluripotent stem cell‐derived lung organoids with HER2 overexpression
Miura, A., Yamada, D., Nakamura, M., Tomida, S., Shimizu, D., Jiang, Y., Takao, T., Yamamoto, H., Suzawa, K., Shien, K., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33713 · Cited by 29
Self-citation
Targeting Receptor Tyrosine Kinases in Cancer
Köstler, W. J., & Zielinski, C. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2_10 · Cited by 26
CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non‐small cell lung cancer
Koga, T., Takeshita, M., Yano, T., Maehara, Y., & Sueishi, K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25447 · Cited by 29
Somatic pharmacogenomics in cancer
Ikediobi, O. N. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.8 · Cited by 29
Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
Takeda, M., Sakai, K., Hayashi, H., Tanaka, K., Tanizaki, J., Takahama, T., Haratani, K., Nishio, K., & Nakagawa, K. (2018) · Oncotarget · doi:10.18632/oncotarget.24958 · Cited by 29
Role of Genotyping in Non-Small Cell Lung Cancer Treatment
Bonanno, L., Favaretto, A. G., Rugge, M., Tarón, M., & Rosell, R. (2011) · Drugs · doi:10.2165/11597700-000000000-00000 · Cited by 29
Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
Bui, K. T., Cooper, W. A., Kao, S., & Boyer, M. J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080192 · Cited by 29
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
Henegouwen, J. M. V. B., Jebbink, M., Hoes, L. R., van der Wijngaart, H., Zeverijn, L. J., Velden, D. L. V. D., Roepman, P., de Leng, W. W. J., Jansen, A. M. L., van Werkhoven, E. D., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.009 · Cited by 28
Braf and erbB2 mutations correlate with smoking status in lung cancer patients
Sasaki, H., Shitara, M., Yokota, K., Okuda, K., Hikosaka, Y., Moriyama, S., Yano, M., & Fujii, Y. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.500 · Cited by 28
ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty
Gilbertson, R. J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-7-508 · Cited by 28
Molecular Pathology of Lung Cancer
Solis, L. M., & Wistuba, I. I. (2012) · Springer eBooks · doi:10.1007/978-1-4419-0787-5_14 · Cited by 27
Self-citation
Epidermal growth factor receptor-targeted therapy
West, C., Joseph, L., & Bhana, S. (2008) · British Journal of Radiology · doi:10.1259/bjr/32798755 · Cited by 27
Systemic and Targeted Therapies for Early-Stage Lung Cancer
Byron, E., & Pinder-Schenck, M. C. (2014) · Cancer Control · doi:10.1177/107327481402100104 · Cited by 27
Pathogenic mechanisms of lung adenocarcinoma in smokers and non-smokers determined by gene expression interrogation
Hu, Y., & Chen, G. (2015) · Oncology Letters · doi:10.3892/ol.2015.3462 · Cited by 27
ERBB2 in Cat Mammary Neoplasias Disclosed a Positive Correlation between RNA and Protein Low Expression Levels: A Model for erbB-2 Negative Human Breast Cancer
Santos, S., Baptista, C. S., Abreu, R. M. V., Bastos, E., Amorim, I., Gut, I. G., Gärtner, F., & Chaves, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083673 · Cited by 27
Hot spot mutations in Finnish non-small cell lung cancers
Mäki‐Nevala, S., Sarhadi, V. K., Rönty, M. J., Kettunen, E., Husgafvel‐Pursiainen, K., Wolff, H. J., Knuuttila, A., & Knuutila, S. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.024 · Cited by 28
Rare Mutations in Non-Small-Cell Lung Cancer
D’Arcangelo, M., D’Incecco, A., & Cappuzzo, F. (2013) · Future Oncology · doi:10.2217/fon.13.16 · Cited by 26
Targeted Therapy for Non-Small Cell Lung Cancer
Noor, Z. S., Cummings, A. L., Johnson, M. M., Spiegel, M. L., & Goldman, J. W. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1700994 · Cited by 27
Molecular Pathogenesis of Early-Stage Non-small Cell Lung Cancer and a Proposal for Tissue Banking to Facilitate Identification of New Biomarkers
Raso, M. G., & Wistuba, I. I. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318074fe42 · Cited by 27
Self-citation
Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants
Chung, B. M. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i5.806 · Cited by 25
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma
Salgia, R. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1181545 · Cited by 25
Therapeutic strategies for afatinib‐resistant lung cancer harboring HER 2 alterations
Torigoe, H., Shien, K., Takeda, T., Yoshioka, T., Namba, K., Sato, H., Suzawa, K., Yamamoto, H., Soh, J., Sakaguchi, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13571 · Cited by 25
Self-citation
MCM5 Aggravates the HDAC1-Mediated Malignant Progression of Lung Cancer
Zhang, L., Li, Q., Zhong, D., Zhang, W., Sun, X., & Zhu, Y. T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.669132 · Cited by 26
Retracted
Ex Vivo Drug Testing of Patient-Derived Lung Organoids to Predict Treatment Responses for Personalized Medicine
Taverna, J. A., Hung, C., Williams, M. H., Williams, R., Chen, M., Kamali, S., Sambandam, V., Chiu, C. H.-L., Osmulski, P. A., Gaczynska, M. E., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2024.107533 · Cited by 26
HER2 Polymorphisms and Breast Cancer in Tunisian Women
Kallel, I., Kharrat, N., AlFadhli, S. M., Rebaï, M., Khabir, A., Boudawara, T. S., & Rebaï, A. (2009) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2009.0069 · Cited by 25
Molecular Tumor Profiling for Prediction of Response to Anticancer Therapies
Walther, Z., & Sklar, J. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318212dd6d · Cited by 25
EGFR/KRAS Mutations and Gefitinib Therapy in Chinese NSCLC Patients
Wang, Z., Wu, Y.-L. L. C., Zhang, G. C., Zhou, Q., Xu, C., & Guo, A. (2008) · Onkologie · doi:10.1159/000116736 · Cited by 25
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive
Santarpía, M., Altavilla, G., Salazar, M., Magrí, I., Pettineo, G., Benecchi, S., & Rosell, R. (2011) · Expert Review of Respiratory Medicine · doi:10.1586/ers.11.27 · Cited by 24
Mechanisms of Disease: signal transduction in lung carcinogenesis—a comparison of smokers and never-smokers
Mountzios, G., Fouret, P. J., & Soria, J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1181 · Cited by 25
ERBB2 kinase domain mutation in a gastric cancer metastasis
Lee, J. W., Soung, Y. H., Kim, S. Y., Park, W. S., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2005) · Apmis · doi:10.1111/j.1600-0463.2005.apm_284.x · Cited by 25
Comprehensive characterization of early-onset lung cancer, in Chinese young adults
Tian, Y., Ma, R., Zhao, W., Wang, S., Zhou, C., Wu, W., Yang, B., Xin, H., Wang, H., Li, P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57309-4 · Cited by 24
Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
Ulivi, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071186 · Cited by 24
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
Lee, K.-K., Jung, H. A., Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.186 · Cited by 24
A Curious Link Between Epidermal Growth Factor Receptor Amplification and Survival: Effect of “Allele Dilution” on Gefitinib Sensitivity?
Kaye, F. J. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji127 · Cited by 24
Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer
Umelo, I. A., Noeparast, M., Chen, G., Renard, M., Geers, C., Vansteenkiste, J., Giron, P., Wever, O. D., Teugels, E., & Grève, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6585 · Cited by 23
Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma
Zhao, M., Zhan, C., Li, M., Yang, X., Yang, X., Zhang, Y., Lin, M., Xia, Y., Feng, M., & Wang, Q. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.68 · Cited by 23
Advances in Treatment of Locally Advanced or Metastatic Non–Small Cell Lung Cancer
Giustini, N., Jeong, A., Buturla, J. A., & Bazhenova, L. A. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.02.003 · Cited by 23
A critical appraisal of prognostic and predictive factors for common lung cancers
Thunnissen, E., Schuurbiers, O. C. J., & Bakker, M. A. D. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02386.x · Cited by 23
HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top
Aliaga, P. T., Spitaleri, G., Attili, I., Corvaja, C., Battaiotto, E., Angelopoulos, P. A., Signore, E. D., Passaro, A., & de Marinis, F. (2025) · Molecules · doi:10.3390/molecules30122645 · Cited by 22
Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma
Shan, L., Qiu, T., Ling, Y., Guo, L., Zheng, B. J., Wang, B., Li, W., Li, L., & Ying, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130447 · Cited by 22
p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer
Cappuzzo, F., Cho, Y. G., Sacconi, A., Alì, G., Siclari, O., Incarbone, M., Destro, A., Terracciano, L., Fontanini, G., Marchetti, A., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318249e13f · Cited by 22
Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases
Shih, A., Telesco, S., & Radhakrishnan, R. (2011) · Cancers · doi:10.3390/cancers3011195 · Cited by 23
RET Is a Heat Shock Protein 90 (HSP90) Client Protein and Is Knocked Down upon HSP90 Pharmacological Block
Alfano, L., Guida, T., Provitera, L., Vecchio, G., Billaud, M., Santoro, M. M., & Carlomagno, F. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2315 · Cited by 22
Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors
Wong, K. (2008) · Lung Cancer · doi:10.1016/s0169-5002(08)70100-4 · Cited by 22
Molecular determinants of lung cancer metastasis to the central nervous system.
Whitsett, T. G., Inge, L. J., Dhruv, H., Cheung, P. Y.-C., Weiss, G. J., Bremner, R. M., Winkles, J. A., & Tran, N. L. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.12 · Cited by 22
Targeted Therapies in Combination with Chemotherapy in Non–Small Cell Lung Cancer
Johnson, D. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0095 · Cited by 22
Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non–Small-Cell Lung Cancer: Study Protocol
Ohashi, K., Hotta, K., Hirata, T., Aoe, K., Kozuki, T., Ninomiya, K., Kayatani, H., Yanai, H., Toyooka, S., Hinotsu, S., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.06.014 · Cited by 21
Self-citation
Updates in the molecular pathology of non-small cell lung cancer
Paver, E. C., O'Toole, S. A., Cheng, X. M., Mahar, A. M., & Cooper, W. A. (2021) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2021.04.001 · Cited by 21
Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity
Takata, M., Chikumi, H., Miyake, N., Adachi, K., Kanamori, Y., Yamasaki, A., Igishi, T., Burioka, N., Nanba, E., & Shimizu, E. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.19238 · Cited by 21
Diagnostic and Predictive Immunohistochemistry for Non–Small Cell Lung Carcinomas
Hung, Y. P., & Sholl, L. M. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000206 · Cited by 21
Anti‑tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations
Ogoshi, Y., Shien, K., Yoshioka, T., Torigoe, H., Sato, H., Sakaguchi, M., Tomida, S., Namba, K., Kurihara, E., Takahashi, Y., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.9908 · Cited by 22
Self-citation
Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients
Scrima, M., Marino, F. Z., Oliveira, D. M., Marinaro, C., Mantia, E. L., Rocco, G., Marco, C. D., Malanga, D., Rosa, N. D., Rizzuto, A., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17093 · Cited by 20
Exploratory analysis of introducing next-generation sequencing-based method to treatment-naive lung cancer patients
written on behalf of the AME Lung Cancer Collaborative Group, Feng, Y., Feng, G., Lu, X., Qian, W., Ye, J., Manrique, C. A., Ma, C., & Lu, Y. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.108 · Cited by 20
PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations
Dong, Q., Yu, P., Ye, L., Zhang, J., Wang, H., Zou, F., Tian, J., & Kurihara, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-42245-3 · Cited by 20
Identification of mutant genes with high‐frequency, high‐risk, and high‐expression in lung adenocarcinoma
Li, G., Yi, S., Yang, F., Zhou, Y., Ji, Q., Cai, J., & Mei, Y. (2013) · Thoracic Cancer · doi:10.1111/1759-7714.12080 · Cited by 20
Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist’s Perspective
Brega, E. F., & Brandao, G. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00182 · Cited by 19
Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance
Shaurova, T., Dy, G. K., Battaglia, S., Hutson, A. D., Zhang, L., Zhang, Y., Lovly, C. M., Seshadri, M., Goodrich, D. W., Johnson, C. S., et al. (2020) · Cancers · doi:10.3390/cancers12030675 · Cited by 20
Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study
Chu, X., Qiang, H., Xie, M., Li, X., Zhao, J., Wu, Y., Zhou, J., Ye, J., Zhao, C., Han, C., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03100-5 · Cited by 19
HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
Vathiotis, I. A., Charpidou, A. G., Gavrielatou, N., & Syrigos, K. N. (2021) · Pharmaceuticals · doi:10.3390/ph14121300 · Cited by 20
Molecular Testing Strategies for Pulmonary Adenocarcinoma: An Optimal Approach With Cost Analysis
Layfield, L. J., Hammer, R., White, S., Furtado, L. V., & Schmidt, R. L. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0218-oa · Cited by 19
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer
Nokin, M., Ambrogio, C., Nadal, E., & Santamaría, D. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.11.005 · Cited by 21
Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer
von Eyben, F. E. (2006) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360600728369 · Cited by 19
The paradigm of personalized therapy in oncology
Gasparini, G., & Longo, R. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.637921 · Cited by 18
Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib
Yuan, B., Zhao, J., Zhou, C., Wang, X., Zhu, B., Zhuo, M., Dong, X.-L., Feng, J., Yi, C., Yang, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00729 · Cited by 17
Elution-free DNA detection using CRISPR/Cas9-mediated light-up aptamer transcription: Toward all-in-one DNA purification and detection tube
Song, J., Song, Y., Jang, H., Moon, J., Kang, H., Huh, Y., Son, H. Y., Rho, H. W., Park, M., Lim, E., et al. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115085 · Cited by 18
Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients
Bhaumik, S., Ahmad, F., & Das, B. R. (2016) · Medical Oncology · doi:10.1007/s12032-016-0828-7 · Cited by 18
A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer
Inoue, Y., Shiihara, J., Miyazawa, H., Ohta, H., Higo, M., Nagai, Y., Kobayashi, K., Saijo, Y., Tsuchida, M., Nakayama, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176525 · Cited by 18
Targeted Therapies in Non-small-Cell Lung Cancer
Hill, A., Gupta, R. V., Zhao, D., Vankina, R., Amanam, I. U., & Salgia, R. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_1 · Cited by 18
Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution
Li, D., Ding, L., Ran, W., Huang, Y., Li, G., Wang, C., Xiao, Y., Wang, X., Lin, D., & Xing, X. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13577 · Cited by 18
Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products
Zhang, S., Jin, S., Griffin, C., Feng, Z., Lin, J., Baratta, M., Brake, R. L., Venkatakrishnan, K., & Gupta, N. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.951 · Cited by 18
Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report
Yan, F., Rinn, K. J., Kullnat, J. A., Wu, A., Ennett, M. D., Scott, E. L., & Kaplan, H. G. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7006 · Cited by 19
Germline Mutations in Driver Oncogenes and Inherited Lung Cancer Risk Independent of Smoking History
Oxnard, G. R., Nguyen, K.-S. H., & Costa, D. B. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt361 · Cited by 19
Detection of E2A-PBX1 fusion transcripts in human non-small-cell lung cancer
Mo, M., Zhao, C. F., Hai‐Meng, Z. H. O. U., Li, H., Hirata, T., Jablons, D. M., & He, B. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-29 · Cited by 18
Targeting Multiple Signal Transduction Pathways in Lung Cancer
Adjei, A. A. (2005) · Clinical Lung Cancer · doi:10.3816/clc.2005.s.006 · Cited by 18
A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
Piha-Paul, S. A., Olwill, S. A., Hamilton, E. P., Tolcher, A. W., Pohlmann, P. R., Liu, S. V., Wurzenberger, C., Hasenkamp, L.-C., Hansbauer, E.-M., Shroff, R. T., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1552 · Cited by 18
Emerging Biomarkers in Personalized Therapy of Lung Cancer
Cagle, P. T., Raparia, K., & Portier, B. P. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_2 · Cited by 16

Authors: Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., Fujisawa, T., Minna, J. D., & Gazdar, A. F.
Affiliations: Okayama University (JP)
1Hamon Center for Therapeutic Oncology Research, Departments of
Chiba University (JP)
Chung Shan Medical University (TW)
The University of Texas MD Anderson Cancer Center (US)
Prince Charles Hospital (AU)
The University of Texas Southwestern Medical Center (US)
ORCID: Majmudar, Kuntal
Suzuki, Makoto
Wistuba, Ignacio I.
Fong, Kwun M.
Toyooka, Shinichi
Minna, John D.
Gazdar, Adi F.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2005-03-01
Volume: 65
Issue: 5
Pages: 1642-1646
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-04-4235
OpenAlex: W2133867160
Cited by: 678
References: 28
Citations by year: 2026: 8 · 2025: 17 · 2024: 13 · 2023: 18 · 2022: 16 · 2021: 36 · 2020: 29 · 2019: 27 · 2018: 36 · 2017: 23 · 2016: 27 · 2015: 46 · 2014: 46 · 2013: 54 · 2012: 34
FWCI: 42.08
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute ((P50-CA70907, P50CA070907, 5U01 CA 8497102)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: HER2 mutation, lung adenocarcinoma, non-small cell lung cancer, EGFR mutation, KRAS mutation, tyrosine kinase domain, never smokers, ethnic differences in mutation frequency, lung cancer etiology, EGFR kinase inhibitors
MeSH terms: Adenocarcinoma, Aged, Aged, 80 and over, Amino Acid Sequence, Female, Humans, Lung Neoplasms, Male, Middle Aged, Molecular Sequence Data, Mutation, Neoplasms, Glandular and Epithelial, Genes, ras, Sequence Homology, Amino Acid, Genes, erbB-2, Genes, erbB-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks